Patents by Inventor Mayumi KITAGAWA

Mayumi KITAGAWA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20230074669
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 9, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20230030720
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: December 5, 2019
    Publication date: February 2, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • Cycloalkane-1,3-diamine derivative
    Patent number: 11236106
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: February 1, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20210269454
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: April 28, 2021
    Publication date: September 2, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • ANTI-CANCER COMPOUNDS AND USES THEREOF
    Publication number: 20190350964
    Abstract: Compounds and their use in modulating the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways to protect normal cells in scenarios such as chemotherapy to kill cancer cells are provided. The compounds inhibit phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) and/or increase phosphoinositide 3-kinase-interacting protein 1 (PIK31P1). Also provided are methods for identifying such compounds, methods of treatment using same and other uses.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 21, 2019
    Inventors: Sang Hyun LEE, Mayumi KITAGAWA, David Michael EPSTEIN
  • Selective anti-cancer compounds
    Patent number: 10308631
    Abstract: A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 4, 2019
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Sang Hyun Lee, Brian William Dymock, Mayumi Kitagawa, Cheng Shang See
  • SELECTIVE ANTI-CANCER COMPOUNDS
    Publication number: 20180179178
    Abstract: A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 28, 2018
    Inventors: Sang Hyun LEE, Brian William DYMOCK, Mayumi KITAGAWA, Cheng Shang SEE